메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 32, Issue 10, 2014, Pages 1091-1092
Cost effectiveness and cancer drugs
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CRIZOTINIB; IMATINIB; TRASTUZUMAB;
EID: 84901596268     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.9932     Document Type: Letter
Times cited : (4)
References (9)
  • 1
    • 84886719809 scopus 로고    scopus 로고
    • Cancer drugs in the United States: Justum pretium - The just price
    • Kantarjian HM, Fojo T, Mathisen M, et al: Cancer drugs in the United States: Justum pretium - The just price. J Clin Oncol 31:3600-3604, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 3600-3604
    • Kantarjian, H.M.1    Fojo, T.2    Mathisen, M.3
  • 2
    • 84891544805 scopus 로고    scopus 로고
    • The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution
    • Pfister DG: The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution. J Clin Oncol 31:3487-3489, 2013
    • (2013) J Clin Oncol , vol.31 , pp. 3487-3489
    • Pfister, D.G.1
  • 3
    • 84855466019 scopus 로고    scopus 로고
    • A phase 3 trial of bevacizumab in ovarian cancer
    • Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
    • (2011) N Engl J Med , vol.365 , pp. 2484-2496
    • Perren, T.J.1    Swart, A.M.2    Pfisterer, J.3
  • 4
    • 24344482346 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of imatinib
    • DOI 10.2165/00003088-200544090-00001
    • Peng B, Lloyd P, Schran H: Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894, 2005 (Pubitemid 41252840)
    • (2005) Clinical Pharmacokinetics , vol.44 , Issue.9 , pp. 879-894
    • Peng, B.1    Lloyd, P.2    Schran, H.3
  • 5
    • 84869381780 scopus 로고    scopus 로고
    • Evidence for therapeutic drug monitoring of targeted anticancer therapies
    • Gao B, Yeap S, Clements A, et al: Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30:4017-4025, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 4017-4025
    • Gao, B.1    Yeap, S.2    Clements, A.3
  • 6
    • 84878241618 scopus 로고    scopus 로고
    • Adjuvant trastuzumab: Does time really matter?
    • Swain SM: Adjuvant trastuzumab: Does time really matter? Oncologist 18:490-492, 2013
    • (2013) Oncologist , vol.18 , pp. 490-492
    • Swain, S.M.1
  • 7
    • 84858297956 scopus 로고    scopus 로고
    • The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
    • Atherly AJ, Camidge DR: The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. BJC 106:1100-1106, 2012
    • (2012) BJC , vol.106 , pp. 1100-1106
    • Atherly, A.J.1    Camidge, D.R.2
  • 8
    • 74249123333 scopus 로고    scopus 로고
    • ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer
    • Solomon B, Varella-Garcia M, Camidge DR: ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450-1454, 2009
    • (2009) J Thorac Oncol , vol.4 , pp. 1450-1454
    • Solomon, B.1    Varella-Garcia, M.2    Camidge, D.R.3
  • 9
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    • Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.J.2    Camidge, D.R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.